The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: Results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up

Annals of Oncology

Volumn 20, Issue 8, 2009, Pages 1344-1351

  Colleoni, Marco ^a   Sun, Z ^b   Martinelli, G ^a   Basser, R L ^c   Coates, A S ^d,e   Gelber, R D ^f   Green, M D ^c   Peccatori, F ^a   Cinieri, S ^a,g   Aebi, S ^h,i   Viale, G ^j   Price, K N ^f   Goldhirsch, A ^a,k  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d International Breast Cancer Study Group   (Switzerland)

^e UNIVERSITY OF SYDNEY   (Australia)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g Division of Medical Oncology   (Italy)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

^k ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

more..

Author keywords

Adjuvant treatment; Dose intensive chemotherapy; Early breast cancer; Endocrine responsiveness

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BIOSYNTHESIS; BREAST TUMOR; DOSE RESPONSE; FEMALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FILGRASTIM; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 69449095872     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp024     Document Type: Article

References (31)

1. Roche H, Viens P, Biron P et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003; 10: 42-47.
2. Nitz U, Mohrmann S, Fischer J et al. Comparison of rapidly cycled tandem high dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 2005; 366: 1935-1944.
3. Zander AR, Kroeger N, Schmoor C et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 2004; 22: 2273-2283.
4. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high risk breast cancer. N Engl J Med 2003; 349: 7-16.
5. Leonard R, Lind M, Twelves C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial. J Natl Cancer Inst 2004; 96: 1076-1083.
6. Peters W, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005; 23: 2191-2200.
7. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26.
8. Goldhirsch A, Wood WC, Gelber RD. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
9. Sorlie T. Molecular classification of breast tumors: Toward improved diagnostics and treatments. Methods Mol Biol 2007; 360: 91-114.
10. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
11. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24: 370-378.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
13. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
15. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004; 5: 465-481.
16. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
17. Anderson J, Cain K, Gelber R, Gelman R. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep 1985; 69: 1139-1146.
18. Pagani O, O'Neill A, Castiglione-Gertsch M et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) trial VI. Eur J Cancer 1998; 34: 632-640.
19. Brincker H, Rose C, Rank F et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol 1987; 5: 1771-1778.
20. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002; 9: 466-472.
21. Fisher B, Sherman B, Rockette H et al. 1-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer 1979; 44: 847-857.
22. Parulekar W, Trudeau ME, Shepherd L et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high risk premenopausal breast cancer patients: Analysis of a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) phase III study. J Clin Oncol 2005; 23: 6002-6008.
23. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
24. Swain SM, Jeong J-H, Geyer CE et al. NSABP-B30: Definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel, and cyclophosphamide in women with operable, node positive breast cancer. Cancer Res 2009; 69(2) (Suppl): 75.
25. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes. Proc Am Soc Clin Oncol 2001; 20 (Abstr 80).
26. Rodenhuis S, Bontenbal M, van Hoesel QG et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588-596.
27. Rose DP, Davis TE. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 1980; 40: 4043-4047.
28. Werner F, Schütt G, Frick M et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 2008; 19: 861-870.
29. Colleoni M, Litman HJ, Castiglione-Gertsch M et al. Duration of adjuvant chemotherapy for breast cancer: A joint analysis of two randomized trials investigating three versus six courses of CMF. Br J Cancer 2002; 86: 1705-1714.
30. Berry DA, Ueno NT, Johnson MM et al. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials. Breast Cancer Res Treat 2007; 106 (Suppl 1): S5 (Abstr 11).
31. Bernhard J, Zahrieh D, Zhang JJ et al. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer 2008; 98: 25-33.